Mindstate is designing psychedelic therapies using their Osmanthus platform, a platform for the prediction of phenomenological psychedelic effects.
Mindstate Design
Osmanthus uses natural history and computational methods to discover new biochemical correlations. Their main focus at present is a molecule similar to MDMA for the treatment of PTSD, with this molecule (MSD-101) believed to have a superior safety profile to MDMA.
On February 12th 2022, Mindstate raised an $11.5 million Seed round.
“Our mission is to map the biological basis of the varieties of the psychedelic experience, and to use that map to pharmacologically design therapeutic states of mind to be applied in medically supervised settings to heal the root causes of mental health disorders.”
Activities
B2B
B2C
Biotech
Drug Discovery
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates
Company News
The Future of Psychedelic Medicine Will Be Drugs You’ve Never Heard Of (Motherboard, 24 January 2022)This article, by the always excellent Shayla Love, discussed the next generation of novel psychedelics. Starting with the many discoveries of Sasha Shulgin, the article then dives deeper into the wishes and hopes of psychedelic companies.
The Mindful Metaverse; Intravenous Psilocin; MindState Design (The Trip Report, 11 February 2022)
The Trip Report reports on three innovative companies in February 2022, TrippVR, Eleusis, and Mindstate Design Labs.